BPC-157, TB-500, and IGF-1 LR3 have no completed human trials at all
Because lapaquistat already has a considerable amount of clinical trial safety data for the treatment of hypercholesterolemia, it is a highly attractive candidate for repurposing as an anti-cryptosporidial drug
doi: 10.3389/fnins.2018.00466 Received 21 March 2018 Accepted 19 June 2018 Published 10 July 2018 Volume 12 - 2018 Edited by Victor Tapias, Cornell University, United States Reviewed by Zezong Gu, University of Missouri, United States
Aloe Vera Extract: A healing and cooling ingredient
Caution: Consult your healthcare practitioner before using this product if you have advanced liver disease
We will monitor your response closely and may recommend follow-up blood tests to ensure youre getting the maximum benefit from your treatment